The agreement includes an upfront payment of $1m with future milestone payments of up to $3m, alongside escalating supply volumes over the next five years.
Genedrive provides a rapid, low cost Point of Care device and aims to provide a gold standard identification of TB and antibiotic resistance testing, according to Epistem.
The Genedrive platform, which has applications across a range of bacterial, viral and fungal, and somatic mutation diseases, and TB test have received CE-IVD registration and regulatory submissions are now in preparation for the Indian market.
The World Health Organisation has publicly recommended that nations incorporate new rapid molecular tests for tuberculosis into their disease testing programs.